NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics Inc (NASDAQ:MGNX) announced its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. The biopharmaceutical company earned $25.19 million during the quarter, compared to analysts' expectations of $10.74 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. View MacroGenics' Earnings History.

MacroGenics is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for MacroGenics.

11 brokers have issued 12-month price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $21.20 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for MacroGenics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

News coverage about MGNX stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for MacroGenics.

MacroGenics saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,180,000 shares, an increase of 14.5% from the January 15th total of 3,650,000 shares. Based on an average daily volume of 575,700 shares, the days-to-cover ratio is presently 7.3 days. Approximately 9.5% of the company's stock are short sold. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Biohaven Pharmaceutical (BHVN), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Aurinia Pharmaceuticals (AUPH), Forty Seven (FTSV), Prestige Consumer Healthcare (PBH), Cambrex (CBM), Epizyme (EPZM), Pacira Biosciences (PCRX), Karuna Therapeutics (KRTX), Xencor (XNCR), Eidos Therapeutics (EIDX), Turning Point Therapeutics (TPTX) and Ironwood Pharmaceuticals (IRWD).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Incyte (INCY), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

MacroGenics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.94%), Sofinnova Investments Inc. (2.40%), Rhenman & Partners Asset Management AB (2.17%), Pinnacle Associates Ltd. (1.75%), FMR LLC (1.70%) and Candriam Luxembourg S.C.A. (1.53%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Jefferies Group LLC, Spark Investment Management LLC, Massachusetts Financial Services Co. MA, Citigroup Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for MacroGenics.

MGNX stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Panagora Asset Management Inc., Oxford Asset Management LLP, Geode Capital Management LLC, Principal Financial Group Inc. and Amia Capital LLP. View Insider Buying and Selling for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $12.01.

MacroGenics has a market capitalization of $587.99 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

The official website for MacroGenics is http://www.macrogenics.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.